Idorsia has decided to reacquire the global rights for the oral endothelin receptor antagonist aprocitentan almost six years after they were sold to Janssen.

The news comes after Idorsia announced potential layoffs, and cost-reduction initiatives, including the sale of its Asia Pacific operations, in July due to “lower than anticipated” sales in H1 2023.

The reacquisition of aprocitentan is expected to provide a much-needed boost to Idorsia’s profits. GlobalData forecasts aprocitentan to generate $241m in sales in 2029.

GlobalData is the parent company of Pharmaceutical Technology.

Idorsia CEO Jean-Paul Clozel said: “Aprocitentan has demonstrated significant and clinically meaningful sustained blood pressure lowering benefits with a good safety profile, particularly suited to the high-risk patient population with resistant hypertension.”

Aprocitentan is currently under review with the US Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) set for 19 December. An EU approval application was filled with the European Medicines Agency (EMA) in January.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Idorsia will pay Janssen up to Sfr306m ($343m), contingent on the EU and US approvals of aprocitentan. Additionally, Janssen will bear no funding obligations and terminate any licence to aprocitentan, except for the treatment of pulmonary hypertension. Idorsia will also give up its revenue share rights to Ponvory (ponesimod), a disease-modifying drug for treating relapsing forms of multiple sclerosis.

Of the total payment, 30% would come from any out-licensing or divestment payment from aprocitentan. The out-licensing or divestment payment for other Idorsia drugs would make 10% of the payout, after the first aprocitentan approval. The remaining consideration would consist of a portion of royalties on total group product net sales, starting from the quarter following the first approval of aprocitentan.